The latest studies available through Cole Eye Institute
The following studies are either currently enrolling patients or are pending approval and should be enrolling shortly:
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Objective: Comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration with respect to the change in best-corrected visual acuity (BCVA) from baseline to Week 48.
Contact: Rishi Singh, MD, 216.445.9497, or Dionne Chandler, MHA, 216.444.3762
Objective: Comparing the efficacy and safety over 108 weeks of a single intravitreal implantation of the NT-503-3 ECT vs. Eylea (aflibercept) injected intravitreally every 8 weeks in patients with recurrent subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who have been previously treated with anti-VEGF injections.
Contact: Rishi Singh, MD, 216.445.9497, or Diana McOwen, BSN, RN, 216.445.2264
Objective: Evaluate the relative efficacy of 10-mg/mL, 40-mg/mL and 100-mg/mL formulations of ranibizumab, delivered via the implant, as measured by the time a patient first requires implant refill according to protocol-defined refill criteria.
Contact: Rishi Singh, MD, 216.445.9497, or Dionne Chandler, MHA, 216.444.3735
Objective: To demonstrate superiority of monthly and every-other-month APL-2 IVT injections compared with sham injections based on the mean change in GA lesion size as measured by FAF and the number and severity of treatment-emergent adverse events.
Contact: Rishi Singh, MD, 216.445.9497, or Amber Bourcier, MPH, 216.445.7176
Objective: Evaluate the retinal vascular dynamics associated with IAI therapy in eyes with diabetic macular edema or macular edema secondary to retinal vein occlusion.
Contact: Justis Ehlers, MD, 216.636.0183, or Laura Stiegel, 216.636.0183
Objective: Assess the feasibility and utility of intraoperative OCT and perioperative OCT in optimizing the management of surgical ophthalmic diseases.
Contact: Justis Ehlers, MD, 216.636.0183, or Jamie Reese, RN, 216.636.0183
Objective: Examine the use of Ozurdex® (dexamethasone intravitreal implant) in patients who are undergoing pars plana vitrectomy for macular edema due to diabetic macular edema.
Contact: Sunil Srivastava, MD, 216.636.2286, or Kim Baynes, 216.444.2566
Objective: This study is to evaluate the safety, tolerability and efficacy of CLS-TA in patients with macular edema following noninfectious uveitis.
Contact: Sunil Srivastava, MD, 216.636.2286, or Kim Baynes, 216.444.2566
Automated Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography
Objective: A prospective, observational, case series investigating the feasibility of utilizing optical coherence tomography (OCT) scans of inflammation in the anterior chamber, vitreous and sclera of patients with uveitis.
Contact: Sunil Srivastava, MD, 216.636.2286, or Kim Baynes, 216.444.2566
Binocular Computer Activities for Treatment of Amblyopia (ATS18)
Objective: To compare the effectiveness of 1 hour/day binocular game play with 2 hours/day patching in children 5-17 years old.
Contact: Fatema Ghasia, MD, 216.444.4363, or Diana McOwen, BSN, RN, 216.445.3762
Molecular Genetics of Eye Diseases
Objective: Study the molecular ophthalmic disorders through the compilation of a collection of DNA, plasma and eye tissue samples from patients and families with a broad range of eye diseases and malformations.
Contact: Elias Traboulsi, MD, 216.444.4363, or Meghan Marino, 216.445.7671
Objective: Identify changes in genes that may lead to uveitis.
Contact: Sunil Srivastava, MD, 216.636.2286, or Meghan Marino, 216.444.2566
Early data shows risk is 73% higher in patients with lupus, 40% higher in patients with rheumatoid arthritis
Identifies weak spots in the cornea before shape change occurs
Researchers to study retinal regeneration in zebrafish with new grant from National Eye Institute
30% of references generated by ChatGPT don’t exist, according to one study
Study followed patients an average of eight years
Studies indicate dramatic results when used topically with or without corticosteroids
53% of participants didn’t need anti-VEGF for six months or longer
Notch pathway inhibition preserves retinal neurons and promotes regrowth in zebrafish